IDYA Stock Risk & Deep Value Analysis
IDEAYA Biosciences Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About IDYA Stock
We analyzed IDEAYA Biosciences Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran IDYA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
IDYA Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk currently is a potential setback in the regulatory pathway for darovasertib. Despite positive Phase 2/3 data and FDA RTOR agreement, a Complete Response Letter (CRL) from the FDA could delay approval significantly, impacting the company's projected revenue timelines and potentially causing a 30-50% stock price decline, jeopardizing the anticipated launch in 2027 and future milestone payments.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Company is currently pre-revenue from product sales, relying heavily on partnership funding and potential future equity raises to cover significant R&D expenses (estimated annual burn of $100M+).
- ⚠
Clinical-stage biotech inherently carries high regulatory risk, as FDA approval for even promising candidates like darovasertib is not guaranteed.
- ⚠
High valuation for a company with no approved products yet, implying significant future growth and success is already priced in.
Upcoming Risk Events
- 📅
Complete Response Letter (CRL) from FDA for darovasertib NDA (H1 2027): a rejection or significant delay in approval would severely impact timelines and investor confidence.
- 📅
Clinical trial failure or significant safety issues in ongoing/upcoming Phase 1/2 trials for pipeline assets (e.g., IDE397, IDE705) (ongoing over next 12-24 months): would diminish pipeline value and increase reliance on darovasertib.
When to Reconsider
- 🚪
Exit if FDA issues a CRL or unexpectedly delays darovasertib approval by more than 12 months.
- 🚪
Sell if any lead pipeline assets (e.g., MAT2A, Pol Theta) report clinical data showing clear lack of efficacy or unacceptable safety profiles, invalidating the synthetic lethality platform beyond darovasertib.
- 🚪
Exit if cash and equivalents drop below $200M (using training data as a proxy for financial health without explicit figures) without a clear, non-dilutive funding pathway identified.
Unlock IDYA Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does IDEAYA Biosciences Inc (IDYA) Do?
Market Cap
$2.49B
Sector
Healthcare
Industry
Biotechnology
Employees
131
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Visit IDEAYA Biosciences Inc WebsiteInvestment Thesis
If darovasertib secures FDA approval under the RTOR program and successfully launches commercially in 2027, it could achieve peak sales of $500M-$1B+ in uveal melanoma, generating significant royalty and milestone revenue for IDEAYA. This success, coupled with the new Roche partnership for MTAP-deleted RAS-mutant pancreatic cancer and other advancing pipeline assets (e.g., Pol Theta, Werner), validates IDEAYA's synthetic lethality platform and could lead to a re-rating to a multi-billion dollar valuation (target $10B within 12-18 months), reflecting its potential to become a leader in precision oncology.
Is IDYA Stock Undervalued?
Unlock the full AI analysis for IDYA
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
IDYA Price Targets & Strategy
12-Month Target
$100.00
Bull Case
$150.00
Bear Case
$45.00
Valuation Basis
Based on 5x estimated FY2030 combined peak sales potential of $4.0B from approved and late-stage pipeline assets, discounted at 25% for clinical/market risk, implying a present valuation of $10.2B.
Entry Strategy
Dollar-cost average between current levels and $25 (historical support). Accumulate on any dips below $30.
Exit Strategy
Take 25% profit at $90-$100, reassess after key catalysts. Stop loss at $20 (below current price and a key psychological level).
Portfolio Allocation
10-15% for aggressive risk tolerance, 5-7% for moderate risk tolerance.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is IDYA Financially Healthy?
Profitability
Operating Margin
-42.02%
Net Margin
-27.77%
Return on Equity
-13.92%
Revenue Growth
3118.14%
EPS
$-1.60
Balance Sheet
Current Ratio
11.34
Quick Ratio
10.97
Other
Beta (Volatility)
-0.05
Does IDYA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is primarily built on its intellectual property and the successful execution of its clinical pipeline. Continued clinical validation and regulatory approvals for multiple assets will strengthen its market position and make it difficult for competitors to replicate its portfolio.
Moat Erosion Risks
- •Clinical failures for key pipeline assets could invalidate the platform's broader potential, eroding confidence and competitive advantage.
- •Patent expiry or successful challenges to its intellectual property by competitors could allow generics or biosimilars to enter the market.
IDYA Competitive Moat Analysis
Sign up to see competitive advantages
IDYA Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bullish: Strong positive sentiment driven by the overwhelmingly positive clinical trial results for darovasertib and the new Roche partnership.
Institutional Sentiment
Positive: Evidenced by Janus Henderson Group's 8.3% beneficial ownership as of 2026-03-31 and the strategic new clinical collaboration with Roche.
Insider Activity (Form 4)
Theodora Ross, Chief Development Officer, reported an option over 297,200 shares at an exercise price of $31.90 expiring 2036-02-26. No recent insider buying or selling reported in the provided data beyond this option grant.
Options Flow
Normal options activity (no specific unusual options activity data provided in the research).
Earnings Intelligence
Next Earnings
Estimated early-August 2026 (for Q2 2026 results)
Surprise Probability
Medium
Historical Earnings Pattern
Highly reactive to pipeline news and regulatory updates, with potential for significant volatility around major clinical data readouts and partnership announcements rather than traditional financial metrics.
Key Metrics to Watch
Competitive Position
Top Competitor
Relies on novel synthetic lethality targets, so direct peers are limited. Larger oncology players (e.g., Novartis, Pfizer) with similar precision medicine focus are indirect competitors and potential partners.
Market Share Trend
Gaining ground in specific synthetic lethality niches; potential to capture significant market share in uveal melanoma due to strong clinical profile.
Valuation vs Peers
Trading at a premium based on pipeline potential and recent clinical success, consistent with high-growth, clinical-stage biotech nearing commercialization.
Competitive Advantages
- •Proprietary synthetic lethality platform and extensive IP portfolio for novel oncology targets.
- •Strategic partnerships with major pharmaceutical companies (GSK, AstraZeneca, Roche) validating its technology and providing non-dilutive funding.
- •Lead asset (darovasertib) showing best-in-class clinical efficacy for a high-unmet-need indication, with an expedited regulatory pathway (RTOR).
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive IDYA Stock Higher?
Near-Term (0-6 months)
- •NDA filing for darovasertib in uveal melanoma (H2 2026): successful filing under RTOR program will further de-risk regulatory pathway and bring it closer to potential market approval.
- •Clinical updates from Roche collaboration in MTAP-deleted RAS-mutant pancreatic cancer (Q4 2026 / Q1 2027): early proof-of-concept or dose escalation data could validate the synergy and expand pipeline value.
Medium-Term (6-18 months)
- •Potential FDA approval for darovasertib in uveal melanoma (Q2-Q4 2027): RTOR could lead to faster approval, generating significant non-dilutive milestone payments and establishing first product-derived royalty stream.
- •Phase 1/2 clinical data readouts for IDE397 (MAT2A) and IDE705 (Pol Theta) programs (H1 2027 - H2 2027): positive data would validate the broader synthetic lethality platform beyond darovasertib, attracting further partnerships/funding.
Long-Term (18+ months)
- •Commercial launch and market penetration of darovasertib (FY2027/2028): if successful, it could achieve peak sales of $500M-$1B+ in uveal melanoma, securing substantial royalty revenues for IDEAYA.
- •Multiple drug approvals from the synthetic lethality pipeline by 2030-2032: if additional candidates (e.g., MAT2A, Pol Theta, Werner) achieve regulatory approval, IDEAYA could become a multi-product precision oncology leader with several billion dollars in combined annual revenue potential.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for IDYA?
- ✓
FDA approval decision date for darovasertib (expected in 2027): a positive decision is critical and will trigger significant re-rating.
- ✓
Updates on commercial launch metrics for darovasertib (post-approval): market penetration, physician adoption rates, and early revenue figures.
- ✓
Phase 2 data readouts for IDEAYA's wholly-owned programs (e.g., Pol Theta, Werner) within 12-18 months: strong efficacy and safety data would validate pipeline depth.
Bull Case Analysis
Sign up free to see the bull case
Competing with IDYA
See how IDEAYA Biosciences Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
IDEAYA Biosciences Inc IDYA | $2.5B | 9.3 | — | — | -27.8% | 3118.1% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How IDEAYA Biosciences Inc Makes Money
IDEAYA Biosciences is a clinical-stage biotechnology company focused on discovering, developing, and commercializing precision oncology medicines using synthetic lethality. They identify novel targets where genetic alterations in cancer cells create vulnerabilities that can be selectively exploited by their drugs, leaving healthy cells unharmed. The company generates revenue primarily through strategic partnerships with larger pharmaceutical companies like GSK, AstraZeneca, and Roche, which provide upfront payments, research funding, and potential milestone payments and royalties on future drug sales. In the future, they aim to commercialize approved products themselves or with partners.
Read Full Business Model BreakdownFAQ
What is the DVR Score for IDEAYA Biosciences Inc (IDYA)?
As of June 8, 2026, IDEAYA Biosciences Inc has a DVR Score of 9.3 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of IDEAYA Biosciences Inc?
IDEAYA Biosciences Inc's market capitalization is approximately $2.5B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does IDEAYA Biosciences Inc use?
IDYA is the ticker symbol for IDEAYA Biosciences Inc. The company trades on the NMS.
What is the risk level for IDYA stock?
Our analysis rates IDEAYA Biosciences Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is IDEAYA Biosciences Inc's revenue growing?
IDEAYA Biosciences Inc has reported revenue growth of 3118.1%. The company is showing strong top-line momentum.
Is IDYA stock profitable?
IDEAYA Biosciences Inc has a profit margin of -27.8%. The company is currently unprofitable.
How often is the IDYA DVR analysis updated?
Our AI-powered analysis of IDEAYA Biosciences Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 8, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for IDYA (IDEAYA Biosciences Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.